Literature DB >> 27110290

The potential of apolipoprotein mimetic peptides in the treatment of atherosclerosis.

Luke J Leman1.   

Abstract

Entities:  

Keywords:  apolipoprotein; atherosclerosis; high-density lipoprotein; inflammation; peptide

Year:  2015        PMID： 27110290      PMCID： PMC4840888          DOI： 10.2217/clp.15.18

Source DB:  PubMed          Journal:  Clin Lipidol        ISSN： 1758-4302


× No keyword cloud information.
  20 in total

1.  A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice.

Authors:  Marcelo J A Amar; Toshihiro Sakurai; Akiko Sakurai-Ikuta; Denis Sviridov; Lita Freeman; Lusana Ahsan; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2014-11-13       Impact factor: 4.030

2.  ApoA1: mimetic peptide reverses adipocyte dysfunction in vivo and in vitro via an increase in heme oxygenase (HO-1) and Wnt10b.

Authors:  Luca Vanella; Ming Li; DongHyun Kim; Giuseppe Malfa; Lars Bellner; Tomoko Kawakami; Nader G Abraham
Journal:  Cell Cycle       Date:  2012-02-15       Impact factor: 4.534

3.  An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice.

Authors:  Shu-Chen Lu; Larissa Atangan; Ki Won Kim; Michelle M Chen; Renee Komorowski; Carolyn Chu; Joon Han; Sylvia Hu; Wei Gu; Murielle Véniant; Minghan Wang
Journal:  J Lipid Res       Date:  2012-01-27       Impact factor: 5.922

4.  Apolipoprotein A-I mimetic peptide inhibits atherosclerosis by altering plasma metabolites in hypercholesterolemia.

Authors:  Zhi-Jun Ou; Li Li; Xiao-Long Liao; Yi-Ming Wang; Xiao-Xia Hu; Qing-Li Zhang; Zhi-Ping Wang; Huan Yu; Xi Zhang; Ping Hu; Ying-Qi Xu; Qiong-Lin Liang; Jing-Song Ou; Guoan Luo
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-04-24       Impact factor: 4.310

5.  Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally.

Authors:  Mohamad Navab; Srinivasa T Reddy; G M Anantharamaiah; Satoshi Imaizumi; Greg Hough; Susan Hama; Alan M Fogelman
Journal:  J Lipid Res       Date:  2011-03-28       Impact factor: 5.922

6.  Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function.

Authors:  Catherine E Watson; Nicole Weissbach; Lise Kjems; Surya Ayalasomayajula; Yiming Zhang; Ih Chang; Mohamad Navab; Susan Hama; Greg Hough; Srinivasa T Reddy; Daniel Soffer; Daniel J Rader; Alan M Fogelman; Alison Schecter
Journal:  J Lipid Res       Date:  2010-11-10       Impact factor: 5.922

7.  Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I.

Authors:  Brian J Van Lenten; Alan C Wagner; Chun-Ling Jung; Piotr Ruchala; Alan J Waring; Robert I Lehrer; Andrew D Watson; Susan Hama; Mohamad Navab; G M Anantharamaiah; Alan M Fogelman
Journal:  J Lipid Res       Date:  2008-07-11       Impact factor: 5.922

8.  A novel approach to oral apoA-I mimetic therapy.

Authors:  Arnab Chattopadhyay; Mohamad Navab; Greg Hough; Feng Gao; David Meriwether; Victor Grijalva; James R Springstead; Mayakonda N Palgnachari; Ryan Namiri-Kalantari; Feng Su; Brian J Van Lenten; Alan C Wagner; G M Anantharamaiah; Robin Farias-Eisner; Robin Farias-Eisener; Srinivasa T Reddy; Alan M Fogelman
Journal:  J Lipid Res       Date:  2013-02-02       Impact factor: 5.922

9.  Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.

Authors:  S Matthijs Boekholdt; Benoit J Arsenault; G Kees Hovingh; Samia Mora; Terje R Pedersen; John C Larosa; K M A Welch; Pierre Amarenco; David A Demicco; Andrew M Tonkin; David R Sullivan; Adrienne Kirby; Helen M Colhoun; Graham A Hitman; D John Betteridge; Paul N Durrington; Michael B Clearfield; John R Downs; Antonio M Gotto; Paul M Ridker; John J P Kastelein
Journal:  Circulation       Date:  2013-08-21       Impact factor: 29.690

10.  Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients.

Authors:  Leanne T Bloedon; Richard Dunbar; Danielle Duffy; Paula Pinell-Salles; Robert Norris; Bruce J DeGroot; Rajesh Movva; Mohamad Navab; Alan M Fogelman; Daniel J Rader
Journal:  J Lipid Res       Date:  2008-03-06       Impact factor: 5.922
View more
  2 in total

1.  ApoA1 Neutralizes Proinflammatory Effects of Dengue Virus NS1 Protein and Modulates Viral Immune Evasion.

Authors:  Diego R Coelho; Pedro H Carneiro; Lucas Mendes-Monteiro; Jonas N Conde; Iamara Andrade; Thu Cao; Diego Allonso; Michael White-Dibiasio; Richard J Kuhn; Ronaldo Mohana-Borges
Journal:  J Virol       Date:  2021-06-10       Impact factor: 5.103

Review 2.  The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy.

Authors:  Yongzheng Lu; Xiaolin Cui; Li Zhang; Xu Wang; Yanyan Xu; Zhen Qin; Gangqiong Liu; Qiguang Wang; Kang Tian; Khoon S Lim; Chris J Charles; Jinying Zhang; Junnan Tang
Journal:  Aging Dis       Date:  2022-04-01       Impact factor: 6.745
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.